background image

Press Releases

Jun 21, 2021

Day One Receives Orphan Designation from the European Commission for DAY101 for the Treatment of Glioma

Read more...

Jun 01, 2021

Day One Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Read more...

May 26, 2021

Day One Announces Pricing of Upsized Initial Public Offering

Read more...

May 11, 2021

Day One Announces First Patient Dosed in FIREFLY-1 Pivotal Phase 2 Clinical Trial of DAY101 in Pediatric Progressive Low-Grade Glioma

Read more...

Apr 12, 2021

Day One Appoints Saira Ramasastry to Board of Directors

Read more...

Feb 23, 2021

Day One Expands Clinical-Stage Oncology Pipeline; Announces Global License Agreement with Merck KGaA, Darmstadt, Germany to Develop and Commercialize MEK Inhibitor Pimasertib

Read more...

Feb 17, 2021

Day One Appoints Charles N. York II as Chief Operating and Financial Officer and Expands Board of Directors with the Addition of Natalie Holles

Read more...

Feb 10, 2021

Day One Announces $130 Million Series B Financing to Accelerate New Targeted Cancer Treatments for Children

Read more...